Skip to content
PeptideAgent

Compounding pharmacies in Colorado

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The Colorado State Board of Pharmacy (Division of Professions and Occupations) regulates compounding pharmacies in Colorado. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Colorado at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Colorado

No verified compounding pharmacies serving Colorado are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Colorado

The Colorado State Board of Pharmacy regulates compounding under the Pharmacy Practice Act (C.R.S. Title 12, Article 280, including section 12-280-120 on compounding and dispensing) and Board rules at 3 CCR 719-1. Colorado has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Under C.R.S. 12-280-133, a prescription drug outlet outside Colorado that ships, mails, or delivers drugs into Colorado is a nonresident prescription drug outlet and must register with the Board, disclose its officers and the pharmacists dispensing to Colorado residents, keep its home-state license valid, and submit its most recent home-state inspection report. Board Rule 5.00.15 accepts an inspection by the home-state board or by a national pharmacy verification program dated within the previous two years and requires an affidavit that the outlet will not ship drugs into Colorado without a patient-specific prescription; an annual third-party inspection is required only for the separate case of distributing compounded products to Colorado veterinarians (Rule 21.00.20). Compounding standards are in Rule 21.00.00 of 3 CCR 719-1, and Rule 21.20.00 (Compounding of Sterile Products) with Rules 21.21.00 and 21.22.00 governs sterile preparations such as injectable peptides. The Board has a permanent rulemaking hearing set for October 1, 2026 on proposed revisions to its compounding rules to align them with recent FDA guidance. [1] [3] [5] [7] [8]

Compounded GLP-1 access in Colorado

Colorado patients using a telehealth GLP-1 program should confirm the prescriber holds a Colorado license and that an out-of-state dispensing pharmacy appears as a registered nonresident prescription drug outlet. The Board of Pharmacy rules (3 CCR 719-1) contain no GLP-1-specific provision, and a 2026 bill to regulate the marketing and distribution of compounded GLP-1 weight-loss medication (SB26-066) was postponed indefinitely in a House committee on May 5, 2026 and did not become law, so federal compounding limits and the general Colorado rules apply. [3] [5] [6] [11] [12]

Research use only sellers in Colorado

Only registered prescription drug outlets, including registered nonresident outlets, may dispense prescription drugs to Colorado patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling and are not dispensed by a pharmacist. Colorado law also bars the sale directly: C.R.S. 12-280-131 says no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug not authorized to move in interstate commerce under federal law, with an exception only for drugs intended solely for investigational use by qualified experts and plainly labeled for investigational use only. [3] [4] [13]

Colorado notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telehealth from a Colorado-licensed provider under the Medical Board's telehealth policies. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [2] [11]

How to check a compounding pharmacy in Colorado

  1. Search the Colorado State Board of Pharmacy (Division of Professions and Occupations) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Colorado requires before it ships to you. [1] [3] [5] [7] [8]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Colorado. [3] [4] [13]

Common questions in Colorado

What does an out-of-state pharmacy need to ship compounded peptides to Colorado?

Registration as a nonresident prescription drug outlet with the Colorado State Board of Pharmacy under C.R.S. 12-280-133. The outlet must submit a recent inspection report from its home-state board or a national pharmacy verification program, keep its home-state license valid, and ship compounded drugs into Colorado only on patient-specific prescriptions, so check the Division of Professions and Occupations license lookup before ordering. [1] [3] [5]

Can a Colorado pharmacy compound BPC-157?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [7] [9] [10]

All peptide legal questions for Colorado

Sources

  1. [1]Colorado State Board of Pharmacy, Division of Professions and Occupations
  2. [2]Colorado Medical Board Policies (Policy 40-03 provider-patient relationship; Policy 40-27 telehealth guidelines, revised August 19, 2021), linked from the Board homepage, accessed 2026-09-22
  3. [3]C.R.S. 12-280-133, Nonresident prescription drug outlet, registration, accessed 2026-09-22
  4. [4]C.R.S. 12-280-131, New drugs, when sales permissible, accessed 2026-09-22
  5. [5]Colorado Secretary of State, Code of Colorado Regulations 3 CCR 719-1, State Board of Pharmacy Rules (current version effective August 21, 2026; Rules 5.00.15, 21.00.00, 21.20.00), accessed 2026-09-22
  6. [6]Colorado General Assembly: SB26-066, Regulation of Compounded Weight-Loss Medication (postponed indefinitely May 5, 2026), accessed 2026-09-22
  7. [7]C.R.S. 12-280-120, Compounding, dispensing, and sale of drugs and devices
  8. [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  10. [10]FDA: Pharmacy Compounding Advisory CommitteeFDA